If your weight has climbed after a brain tumor, its surgery, radiation or a brain injury, and diet and exercise haven't moved it, the condition has a name: acquired hypothalamic obesity. On March 19, 2026, the FDA approved the prescription medicine Imcivree (setmelanotide) for adults and children aged 4 and older who have it. Rhythm Pharmaceuticals reported two-year results on November 16, 2026. In the long-term extension, 81 of 125 patients completed two years. Mean BMI change was -18.8% for people on continuous treatment and -16.5% for people who switched from placebo. Here's what those numbers mean, how the medicine is designed to work, and what to ask your doctor.
What is acquired hypothalamic obesity?
The hypothalamus is a brain region that helps control hunger, energy use, body temperature, sleep and some pituitary hormones. When it's damaged, weight can climb and keep climbing.
NORD's overview of the condition, last updated June 23, 2025, describes it as excess weight gain after injury to the hypothalamus. The weight gain resists diet and exercise. Reuters, reporting on November 16, 2026, calls it a rare disease that causes excess, sustained weight gain after injuries such as tumor growth or stroke.
NORD lists the causes as brain tumor surgery (especially craniopharyngioma), radiation, traumatic brain injury, infection, inflammation or bleeding. Radiation-related weight gain can show up months to years later.
The FDA's clinical review of Imcivree estimates 5,000 to 10,000 people in the U.S. have this condition. It also says weight gain is most dramatic in the first year after surgery and can continue for 8 to 12 years. In one U.S. registry study cited in that review, 86% of patients developed the condition after a brain tumor or its surgical treatment, and 72% of those tumors were craniopharyngiomas.
Why doesn't diet and exercise work for it?
The FDA's clinical review says lifestyle changes are the standard of care, but they have “failed to result in consistently meaningful and sustained reductions in BMI.” The problem is the appetite system, not your effort.
The review explains that structural damage disrupts the brain circuits that control appetite, including a hormone pathway that normally reduces eating and raises energy use. A 2025 Endocrine Reviews paper adds that hypothalamic damage can bring fatigue, daytime sleepiness, low body temperature and lower energy use, all of which may contribute to weight gain. Some people also have hunger that doesn't ease after they eat.
The FDA review also links severe obesity from this condition to heart disease, type 2 diabetes and fatty liver disease. That's why the weight matters beyond the scale.
What did the FDA approve, and when?
Here are the core facts as of November 17, 2026.
| Item | What it says | Source and date |
|---|---|---|
| Medicine | Imcivree (setmelanotide), a once-daily injection under the skin | FDA clinical review; FDA approval letter, March 19, 2026 |
| Maker | Rhythm Pharmaceuticals | FDA approval letter, March 19, 2026 |
| New approved use | Reduce excess body weight and maintain weight reduction long term in adults and pediatric patients 4 years and older with acquired hypothalamic obesity | FDA approval letter, March 19, 2026 |
| Earlier approved uses | Obesity due to POMC, PCSK1 or LEPR deficiency, and Bardet-Biedl syndrome | FDA clinical review |
| Two-year results | 81 of 125 extension patients completed two years | Rhythm, reported November 16, 2026 |
| Estimated U.S. prevalence | 5,000 to 10,000 people | FDA clinical review |
The FDA approval letter was signed March 19, 2026, and the approval took effect that day. Rhythm's application was received June 20, 2025. A major amendment dated October 27, 2025 pushed the review goal date back three months.
The FDA's clinical review recommended approval. It was based on one randomized, double-blind, placebo-controlled trial, RM-493-040, plus supporting data from the related approved uses.
What did the two-year results show?
Rhythm reported these results at ObesityWeek 2026 in Washington, D.C. Reuters covered them on November 16, 2026. Rhythm presents the figures as changes in BMI, a height-and-weight measure. Adults and children are reported separately.
| Group | Completed two years | Mean BMI change, all ages | Adults | Pediatric BMI z-score change |
|---|---|---|---|---|
| Continuous setmelanotide | 54 | -18.8% | -21.2% | -1.71 |
| Switched from placebo after year one | 27 | -16.5% | -21.0% | -1.49 |
The first-year trial counts differ by outlet. Reuters reports 142 participants aged 4 and older were randomized. The NEJM phase 3 trial abstract reports 120 participants assigned, 81 to setmelanotide and 39 to placebo. At 52 weeks, its mean BMI change was -16.5% on setmelanotide and 3.3% on placebo. That -16.5% is a separate measurement from the two-year figure for the switched group. The FDA review gives the adjusted difference between groups as -18.40% (95% CI -21.94 to -14.85).
After year one, everyone in the extension received setmelanotide. So the two-year groups are compared by how they started, not against a placebo group. The NEJM abstract reports that hunger scores, measured in participants 12 and older, fell by an average of 2.73 points on setmelanotide and 1.45 on placebo over 52 weeks. Rhythm's ENDO 2026 release reports that at one year, 43.8% of patients on setmelanotide reached the overweight or healthy weight category, compared with 13.5% on placebo.
These two-year numbers are BMI changes, not pounds, and they cover only the 81 of 125 patients who had completed two years at the time of analysis.
How does setmelanotide work?
Setmelanotide is a synthetic medicine that targets a receptor called MC4R. Reuters says it's designed to activate the MC4R pathway. Rhythm's 2020 approval release describes that pathway as the one that regulates hunger, energy use and body weight.
In acquired hypothalamic obesity, the FDA review describes two ways the drug is expected to work. It reaches the receptors still working in the hypothalamus, and it reaches receptors in other brain areas. The review says setmelanotide lasts longer in the body than alpha-MSH, the body's own signal that reduces eating. It puts the half-life, the time for half of the drug to clear, at about 11 hours.
An earlier phase 2 study in 18 patients, published in The Lancet Diabetes and Endocrinology, found a mean BMI reduction of 15% across all patients. Its frequent side effects were nausea (61%), vomiting (33%), skin darkening (33%) and diarrhea (22%).
What are the side effects of Imcivree?
The FDA clinical review lists these side effects from the placebo-controlled trial.
| Side effect | Setmelanotide group | Placebo group |
|---|---|---|
| Skin darkening (hyperpigmentation) | 58% | 10% |
| Nausea | 55% | 25% |
| Vomiting | 38% | 19% |
| Headache | 37% | 31% |
| Darkening of an existing mole | 15% | 6% |
| Serious acute adrenal insufficiency | 5% | 0% |
| High sodium (hypernatremia) | 5% | 4% |
| Low sodium (hyponatremia) | 6% | 2% |
The NEJM abstract reports adverse events in 100% of the setmelanotide group and 90% of the placebo group. Serious adverse events were 28% and 8%. The most common were skin darkening, nausea, vomiting and headache.
The label carries several warnings:
- Adrenal and sodium changes. The FDA review says acute adrenal insufficiency and sodium imbalance were added to the label's warnings for the new use.
- Sexual arousal changes. The 2020 approval release quotes the label: seek emergency care if an erection lasts longer than 4 hours.
- Depression and suicidal thoughts. The label says to monitor for new or worsening depression.
- Skin and mole changes. The label says skin darkening is reversible after stopping the drug.
Ask your doctor how they monitor adrenal function and sodium levels, and how they'll handle nausea, vomiting and skin darkening.
Who is it for, and is it a general weight-loss drug?
Imcivree's approved uses are obesity from POMC, PCSK1 or LEPR deficiency, obesity from Bardet-Biedl syndrome, and acquired hypothalamic obesity. The 2026 approval covers ages 4 and older for the new use. The 2026 Imcivree label PDF lists the indication.
The approval is not a general weight-loss approval. The 2020 approval release quotes the label's limits, which exclude other types of obesity, including general (polygenic) obesity. It also says the medicine isn't approved for neonates or infants, and isn't recommended while breastfeeding. The label says to stop when pregnancy is recognized, unless the benefits outweigh the risks to the fetus.
An international diagnostic criteria paper from 2026 defines the condition. It requires a tumor or injury affecting the hypothalamus on MRI, plus a rapid and lasting rise in BMI during the first 12 months. The FDA review describes two peak ages for craniopharyngioma, in childhood (5 to 9 years) and in older adults (55 to 69 years).
Common mix-ups to avoid
- The 2020 and 2026 approvals cover different groups. The 2020 approval covered genetic obesity. The 2026 approval adds weight gain from hypothalamic injury.
- Older overviews may be out of date. NORD's overview was last updated June 23, 2025, before the approval. Its line that no FDA-approved treatment exists is out of date. The FDA approval letter is the current word.
- Ordinary weight loss is a different subject. The label limits the medicine to the groups named above.
- “Resetting” the hypothalamus is a different subject. The research here is about a prescription medicine tested in trials for weight gain caused by hypothalamic damage. It doesn't cover supplements or natural resets.
How much does Imcivree cost?
Prices change, and what you pay depends on your plan and pharmacy. Ask your prescriber's office or a pharmacist for the current cost and what your insurance covers.
Questions to bring to an endocrinologist
An endocrinologist, or a pediatric endocrinologist for children, decides whether this fits your case. Bring these questions:
- Does my history match the diagnostic criteria, including the brain injury or tumor and my weight rise in the first year?
- Am I in the approved age and diagnosis group?
- How will you monitor adrenal function and sodium levels?
- How will you handle nausea, vomiting and skin darkening?
- How will my pituitary, sleep and temperature symptoms be managed alongside my weight?
- What will the medicine cost me, and what does my insurance cover?
Your next step
Before your appointment, write down when the brain injury, tumor or surgery happened, when your weight started climbing, and what diet and exercise you've already tried. Track your weight on the same scale each week, and bring that log and the two-year table above to your visit.
If you want a broader plan to run alongside any medical care, the best weight loss plan for you guide covers the options. If you're comparing how weight-loss trials report percent change, the retatrutide trial results page lays those numbers side by side.
By the New Life Wellness Guide Editorial Team